Dositinib Mesylate Tablets
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Dositinib Mesylate Tablets, covering 2025-11-17 to 2025-11-17. Get the full timeline:
Most recent: Clinical Trial Update: A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation [Phase 1, Phase 2]